Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell sector : Consumer services save search
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
Published: 2023-08-17 (Crawled : 15:00) - biospace.com/
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: -1.54%
H: 4.53%
C: -1.56%
institute cell research car-t technology therapeutics
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
Published: 2023-07-26 (Crawled : 11:00) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 1.14%
H: 9.01%
C: -3.94%
cell car-t therapeutics
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma CellsMT-601 showed anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro
Published: 2023-05-31 (Crawled : 11:00) - biospace.com/
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 39.11%
H: 5.41%
C: -3.78%
mt-601 candidate pre-clinical cell cd19 therapeutics in vitro
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
Published: 2023-05-31 (Crawled : 11:00) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 39.11%
H: 5.41%
C: -3.78%
mt-601 candidate pre-clinical cell therapeutics
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
Published: 2022-11-22 (Crawled : 13:00) - biospace.com/
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 13.6%
H: 0.0%
C: -12.72%
mt-601 treatment fda clearance therapeutics therapy cancer pancreatic
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
Published: 2022-08-04 (Crawled : 21:00) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 81.82%
H: 10.0%
C: -10.0%
mt-601 treatment fda clearance therapeutics therapy
Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting
Published: 2022-05-04 (Crawled : 15:00) - biospace.com/
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 1.0%
H: 8.8%
C: 6.93%
therapeutics therapy international
Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting
Published: 2021-11-18 (Crawled : 22:00) - biospace.com/
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 0.0%
H: 0.74%
C: -7.35%
ema phase 1 t-cell
Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Published: 2021-04-27 (Crawled : 00:00) - prnewswire.com
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 0.0%
H: 10.53%
C: 8.91%
therapy t-cell
Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
Published: 2021-01-13 (Crawled : 15:00) - biospace.com/
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 8.85%
H: 2.39%
C: -0.48%
therapy t-cell
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.